Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.46 |
| ▸ | DRD3 | P35462 | 3/20 | 0.46 |
| ▸ | DRD5 | P21918 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.45 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.45 |
| ▸ | AGER | Q15109 | 6/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | DRD4 | P21917 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | FPR2 | P25090 | 2/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6844250 | 0.94 | SIGMAR1 (0.46) | DRD2DRD3DRD5SIGMAR1P2RX7 | |
| SCHEMBL6846745 | 0.83 | DRD2 (0.55) | DRD2DRD3DRD5SIGMAR1AGER | |
| SCHEMBL6843574 | 0.80 | HTT (0.59) | DRD2DRD3P2RX7AGERCYP1A2 | |
| SCHEMBL6839346 | 0.79 | P2RX7 (0.56) | DRD2DRD3P2RX7AGERCYP1A2 | |
| SCHEMBL6844242 | 0.75 | LMNA (0.60) | P2RX7AGERCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL6843887 | 0.73 | AGER (0.49) | AGERCYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL15748095 | 0.73 | DRD2 (0.75) | DRD2DRD3DRD5SIGMAR1DRD4 | |
| Hydrochloric Acid SCHEMBL17103181 | 0.73 | DRD2 (0.74) | DRD2DRD3DRD5SIGMAR1DRD4 | |
| SCHEMBL17103164 | 0.73 | DRD2 (0.74) | DRD2DRD3DRD5SIGMAR1DRD4 | |
| SCHEMBL8335130 | 0.73 | CETP (0.41) | DRD2AGERDRD4MAPK1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040116443-A1 | Dopamine D4 ligands for the treatment of novelty-seeking disorders | PFIZER INC | 2004-06-17 | — | — | US | claimed |
| US-20030158208-A1 | Dopamine D4 ligands for the treatment of novelty-seeking disorders | PFIZER INC. | 2003-08-21 | — | — | US | claimed |
| EP-0775118-B1 | BENZIMIDAZOLE DERIVATIVES HAVING DOPAMINERGIC ACTIVITY | PFIZER (US) | 2003-06-04 | — | — | EP | claimed |
| US-20020049209-A1 | Dopamine D4 ligands for the treatment of novelty-seeking disorders | PFIZER INC. | 2002-04-25 | — | — | US | claimed |
| EP-1177792-A2 | Dopamine D4 Ligands for the treatment of novelty-seeking disorders | Pfizer Products Inc. (US) | 2002-02-06 | — | — | EP | claimed |
| EP-0775118-A1 | BENZIMIDAZOLE DERIVATIVES HAVING DOPAMINERGIC ACTIVITY | PFIZER INC. (US) | 1997-05-28 | — | — | EP | claimed |
| WO-1996004250-A1 | BENZIMIDAZOLE DERIVATIVES HAVING DOPAMINERGIC ACTIVITY | PFIZER INC. (US) | 1996-02-15 | — | — | WO | claimed |
| US-20040116443-A1 | Dopamine D4 ligands for the treatment of novelty-seeking disorders | PFIZER INC | 2004-06-17 | — | — | US | disclosed |
| US-20030158208-A1 | Dopamine D4 ligands for the treatment of novelty-seeking disorders | PFIZER INC. | 2003-08-21 | — | — | US | disclosed |
| EP-0775118-B1 | BENZIMIDAZOLE DERIVATIVES HAVING DOPAMINERGIC ACTIVITY | PFIZER (US) | 2003-06-04 | — | — | EP | disclosed |
| US-6548502-B2 | Preventing disorder selected from pathological gambling, attention deficit disorder with hyperactivity disorder, substance addiction such as drug and alcohol and sex in a mammals by administering pyrido(1,2-a) pyrazine derivatives | PFIZER INC | 2003-04-15 | — | — | US | disclosed |
| US-20020049209-A1 | Dopamine D4 ligands for the treatment of novelty-seeking disorders | PFIZER INC. | 2002-04-25 | — | — | US | disclosed |
| EP-1177792-A2 | Dopamine D4 Ligands for the treatment of novelty-seeking disorders | Pfizer Products Inc. (US) | 2002-02-06 | — | — | EP | disclosed |
| EP-0775118-A1 | BENZIMIDAZOLE DERIVATIVES HAVING DOPAMINERGIC ACTIVITY | PFIZER INC. (US) | 1997-05-28 | — | — | EP | disclosed |
| WO-1996004250-A1 | BENZIMIDAZOLE DERIVATIVES HAVING DOPAMINERGIC ACTIVITY | PFIZER INC. (US) | 1996-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049209-A1 | Dopamine D4 ligands for the treatment of novelty-seeking disorders | SLC6A3, DRD4, DRD2 | DRD2 3/4885DRD3 6/4885DRD5 11/4885 |
| US-20030158208-A1 | Dopamine D4 ligands for the treatment of novelty-seeking disorders | SLC6A3, DRD4, DRD2 | DRD2 3/4885DRD3 6/4885DRD5 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.